Suicide Gene Therapy for Cancer – Current Strategies

Paul Zarogoulidis1, Kaid Darwiche2, Antonios Sakkas3, Lonny Yarmus4, Haidong Huang5, Qiang Li5, Lutz Freitag2, Konstantinos Zarogoulidis1, Marek Malecki6,7

1Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, EU; 2Department of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital, University Duisburg-Essen, Essen, Germany, EU; 3Pathology Department, “G. Papanikolaou” General Hospital, Thessaloniki, Greece, EU; 4Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, USA; 5Department of Respiratory Diseases, Shanghai Hospital/First Affiliated Hospital of the Second Military Medical University, Shanghai, China; 6Phoenix Biomolecular Engineering Foundation, San Francisco, CA, USA; 7University of Wisconsin, Madison, WI, USA

Abstract

Current cancer treatments may create profound iatrogenic outcomes. The adverse effects of these treatments still remain, as the serious problems that practicing physicians have to cope with in clinical practice. Although, non-specific cytotoxic agents constitute an effective treatment modality against cancer cells, they also tend to kill normal, quickly dividing cells. On the other hand, therapies targeting the genome of the tumors are both under investigation, and some others are already streamlined to clinical practice. Several approaches have been investigated in order to find a treatment targeting the cancer cells, while not affecting the normal cells.

Suicide gene therapy is a therapeutic strategy, in which cell suicide inducing transgenes are introduced into cancer cells. The two major suicide gene therapeutic strategies currently pursued are: cytosine deaminase/5-fluorocytosine and the herpes simplex virus/ganciclovir. The novel strategies include silencing gene expression, expression of intracellular antibodies blocking cells’ vital pathways, and transgenic expression of caspases and DNases. We analyze various elements of cancer cells’ suicide inducing strategies including: targets, vectors, and mechanisms. These strategies have been extensively investigated in various types of cancers, while exploring multiple delivery routes including viruses, non-viral vectors, liposomes, nanoparticles, and stem cells. We discuss various stages of streamlining of the suicide gene therapy into clinical oncology as applied to different types of cancer.

Moreover, suicide gene therapy is in the center of attention as a strategy preventing cancer from developing in patients participating in the clinical trials of regenerative medicine. In oncology, these clinical trials are aimed at regenerating, with the aid of stem cells, of the patients’ organs damaged by pathologic and/or iatrogenic factors. However, the stem cells carry the risk of neoplastic transformation. We discuss cell suicide inducing strategies aimed at preventing stem cell-originated cancerogenesis.

Keywords: Suicide gene therapy; Cancer; Transporters; Viral vectors; Non-viral vectors; Regenerative medicine

Introduction

The cornerstone of cancer treatment still remains the integrated multimodality approach with chemotherapy, radiotherapy and surgery. Neo-adjuvant and adjuvant treatments are applicable in several cancer types and complete surgical resection offers prolonged survival. However, chemotherapy and radiotherapy have iatrogenic adverse effects associated with the current mode of administration. As an example may serve cisplatin based chemotherapy. It may cause nausea and emesis to the degree, which may require reduction of the doses below those most effective or interruption of the therapy. As another example may serve radiotherapy of. In addition to the iatrogenic symptoms of radiation sickness, the patients’ treatment has may have to be postponed until the bone marrow recovers [1]. Moreover, bone marrow suppression in many cases requires hospitalization with additional costs for the national health system [2,3].

In an effort to reduce the adverse effects, novel routes of administration were investigated in many types of cancer with different strategies, with the main concept being to localize the treatment [4-14]. Until now, the approved cancer treatment modality for chemotherapy drugs is intravenous and in some cases the oral route. However, breakthroughs in revealing the genome mutations of tumors have indicated specific mutated populations. The era that we are currently experiencing is called ‘the era of the genome’ with multiple genetic mutations and pathways being discovered in populations of people [15]. In these populations certain pathways were altered and pharmaceuticals were designed in order to target these mutations [16-18]. Pharmacogenetics links specific genetic traits of with efficacy of specific drugs [19]. The major limitations of this treatment approach are small populations of people carrying with specific gene defined high susceptibility to cancer. Continued investigations of cancer evolution keep revealing mechanisms that maybe utilized in order to block chemotherapy resistance and sensitize tumors to chemotherapy and radiotherapy [20].

The major breakthrough in gene therapy modality was designing...
suicide gene therapy. The safety and effectiveness of cancer treatment became reality through this modality. In the suicide gene therapy, the therapeutic transgenes have the ability to convert a non-toxic pro-drug, which penetrates the tumor, into cytotoxic drug or to express the toxic gene expression product. This action is taking place inside the tumor with the help of an administered viral or bacterial cell suicide inducing gene. The normal cells are not affected [21-23]. The suicide gene therapy has been investigated in several cancer types; a) colon [8,24,25], b) liver [9,26,27], c) lung [28,29], d) medulloblastomas [30], e) neuroendocrine [31], f) spinal cord tumors [32], g) prostate [33], h) breast [34,35], i) bladder [36], j) brain [37], k) gliomas [38-40], l) head and neck [41], m) sarcomas [42], and ovaries [108,111-112]. The suicide gene therapy has been investigated as: a) anti-vascular endothelial treatment [43,44], b) immune stimulation with interleukin-7 (IL-7) [45] and interleukin-12 (IL-12) [46]. Furthermore, suicide gene therapy has been proven to be more efficient in chemotherapy resistant cancer cell lines [47] and to enhance radiotherapy [48]. Additional control of micrometastases, through the efficient local control of microenvironment, has also been achieved with suicide gene therapy [49]. Finally, suicide gene therapy has been explored by using the state of the art technology of nanoparticles, either as a mode to passively transport the suicide gene formulation, or as a mode to efficiently display the diffusion of the formulation [43,50,51].

Basic Strategies to Induce Cancer Cell Suicide

Cytosine deaminase and thymidine kinase

The basic concept of suicide gene therapy is the introduction of viral or bacterial genes into tumors cells, which in turn convert a non-toxic pro-drug to a toxic one (Figure 1). There are systems that have been extensively investigated: the cytosine deaminase gene (CD) of Escherechia coli, which converts the pro-drug 5-Fluorocytosine (5-FC) to 5-Fluorouracil (5-FU) and the herpes simplex virus thymidine kinase gene (HSV-tk), which converts ganciclovir (GCV) to ganciclovir monophosphate, converted by the cancer cells’ enzymes to ganciclovir triphosphate. The HSV-tk/GCV system induced a delay in the S phase and G2-phase and the apoptosis observed is not a direct result of the system activation, but a result of the delayed proliferation process. In addition, mitochondrial damage was observed to be induced [55] and caspase-8, Chk1 activation was associated with extensive cell death [56,57].

The cytosine deaminase can be found in fungi and bacteria, but not in mammalian cells. The non-toxic 5-FC is transformed to the toxic 5-FU. The cellular enzymes will then further process the formulation to three cytotoxic antimetabolites: 1) 5-FdUDP, 2) 5-FUTP and 3) 5-FdUMP. The CD suicide therapy cytotoxic effects are based on three properties of the system: a) formation of (5-FU) DNA - b) 5-FU DNA complexes and c) thymidylate synthase. The mitochondrial pathways are down-regulated through the control of Bcl-2 [58] and heat shock protein 90-beta is activated, contributing to tumor regression [59]. Another methodology investigated was to target the erb-2 oncogene over-expression with CD-5-FU over [60]. The cytosine deaminase/5-FU system has been improved by including the gene uracil phosphoribosyltransferase (UPRT) [61]. Another method was to combine the UPRT with the yeast enzymatic activities of CD [28]. Finally, the combination of both systems delivered simultaneously has also been achieved [62,29]. Furthermore, there are other systems that are not widely used such as: a) Varicella-Zoster virus thymidine kinase (VZV-tk), b) Purine nucleoside phosphorylase (PNP), c) Carboxypeptidase A, d) Carboxypeptidase G2, e) Linamarase, f) Beta-Galatosidase, g) Nitroreductase and h) Hepatic cytochrome P450-2B1

Transport systems

There are currently two main vehicles utilized to deliver cell suicide genes: viral vectors and non-viral vectors. The viral vectors have been derived from poxviruses, herpes simplex virus, lentivirus, retroviruses, vaccinia virus, adenovirus and adeno-associated viruses. Oncolytic viruses have been also used and they are capable of bearing tumor specificity. However, the major problem is generation of neutralizing antibodies (nAbs), which are formed due to the immunogenicity and inflammatory toxicity. The formation of nAbs is dependent on the viral vector load and viral vector type [63,64]. The non-viral vectors are widely used with three different approaches: 1) naked DNA, 2) physical methods and 3) chemical methods. Non-viral vectors include the cationic liposomes and cationic polymers. These two delivery systems have a positive charge, which interacts with the negative charge of the plasmid DNA. These are capable of transporting large amounts of DNA and can be modified in numerous ways according to the investigators’ design. Additional delivery systems have been designed for these vectors [65,66]. However, safety concerns of non-viral vectors are still under consideration for several cell lines and toxicity is correlated with the kDa size of the polymers [67]. Moreover, other non-viral have been investigated with: 1) exosomes, 2) erythrocyte ghosts, 3) bacteria, 4) bacteriophages, 5) virus-like particles, 6) antibodies, 7) immuno-transporters for suicide gene therapy. They have the ability to infect the hypoxic cancer cells and have presented efficient antitumor activity against chemo-resistant cancer cell lines [34,36].

Cellular vehicles, that have been proposed as transport systems, are summarized as follows: a) bone marrow stromal cells (MSCs) which exhibit the ability of homing to the tumor sites [39,68], b) neural stem cells (NSCs) which have an inherent tumor tropism [38,37], c) endothelial progenitor precursor and d) blood outgrowth endothelial cells. The last two target the vascular tumor tissue and are under investigation for clinical applications [43,44].

Currently nanoparticles are being investigated as efficient gene transporters for suicide gene therapy. They have the ability to efficiently
<table>
<thead>
<tr>
<th>Author</th>
<th>Cells lines</th>
<th>Design</th>
<th>Result</th>
<th>Transport</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walther W. et al.</td>
<td>MCF-7, HCT116, SKMel-5, Panc-1</td>
<td>In Vitro, In Vivo</td>
<td>Effective against MCF-7, HCT116 (overexpressing claudin-3, -4)</td>
<td>wtCPE, optCPE</td>
<td>[81]</td>
</tr>
<tr>
<td>Mader R.M. et al.</td>
<td>CCL227 (with low and intermediate phenotypes)</td>
<td>In Vitro</td>
<td>Effective with 100% Activation</td>
<td>Adenoviral cosmid</td>
<td>[8]</td>
</tr>
<tr>
<td>Bondanza A. et al.</td>
<td>Leukemia (mouse)</td>
<td>In Vitro, In Vivo</td>
<td>Effective with IL-7 receptor expression (HA-1, H-Y)</td>
<td>Herpes simplex virus Thymidine kinase (tk)</td>
<td>[45]</td>
</tr>
<tr>
<td>Xu Y. et al.</td>
<td>Lewis Lung Cancer A549</td>
<td>In Vitro, In Vivo</td>
<td>Combination IL-12 and suicide gene therapy enhances the antitumor effect as a factor modifying the tumor microenvironment</td>
<td>AdCMV(-), AdhTERTHRP, AdCMV-ml-12</td>
<td>[46]</td>
</tr>
<tr>
<td>Sia KC. et al.</td>
<td>HCC 26-1004</td>
<td>In Vitro, In Vivo</td>
<td>Effective HSV-1 ampiclon viral vector and 5-FU administration</td>
<td>HSV-1 ampiclon viral Vector coupled with yCD</td>
<td>[9]</td>
</tr>
<tr>
<td>Li S. et al.</td>
<td>C17.2 NSC line</td>
<td>In Vitro, In Vivo</td>
<td>ATRA enhanced the HSV-8k/GCV expression (HA-1, H-Y)</td>
<td>Lipid-complexed plasmid Bearing IFN-β and suicide gene co-administered with ganciclovir (ISG)</td>
<td>[42]</td>
</tr>
<tr>
<td>Finocchiaro M.E.L. et al.</td>
<td>sarcoma</td>
<td>In Vivo</td>
<td>Effective Microenvironment Control and Distant metastasis</td>
<td>Lipid-complexed plasmid Bearing IFN-β and suicide gene co-administered with ganciclovir (ISG)</td>
<td>[39]</td>
</tr>
<tr>
<td>Leng A. et al.</td>
<td>Human colon carcinoma (Lovo) cell line</td>
<td>In Vitro, In Vivo</td>
<td>Anti-VEGF-A- Suicide gene therapy</td>
<td>5-FC, CPNP-shVEGF-CDK</td>
<td>[43]</td>
</tr>
<tr>
<td>Liu T. et al.</td>
<td>SGC7901 human gastric Cancer cell line</td>
<td>In Vivo, In Vivo</td>
<td>Anti-VEGF- Suicide gene therapy</td>
<td>5-FC, triple gene vector ExpressingVEGF-shRNA and fusion suicide gene yCDglyTK delivered by CPNPs</td>
<td>[44]</td>
</tr>
<tr>
<td>Finzi et al.</td>
<td>Human HT29 and murine DHDK12 pro-b</td>
<td>In Vitro, In Vivo</td>
<td>MTX, aphidicolin and ara-C. The rate of apoptosis increased two-fold in MTX-treated DHDK12 cells After treatment with GCV.</td>
<td>HSVilk-GCV</td>
<td>[25]</td>
</tr>
<tr>
<td>Niu H. et al.</td>
<td>VX2 liver cancer</td>
<td>In Vivo</td>
<td>Effective with lipidol embolism and WtTp53</td>
<td>TK/CD plus intraperitoneal Injection of GCV at 100mg/(kg.d) and 5-FU at 500mg/(kg.d)</td>
<td>[26]</td>
</tr>
<tr>
<td>Marukawa Y. et al.</td>
<td>HCC</td>
<td>In Vivo, In Vivo</td>
<td>Effective Mac-1, CD4, CD8a-positive and TNF increase</td>
<td>-HSV-8k/GCV and MCP-1 -Ad harboring human MCP-1 and the membrane-spanning domain of the tumor cell surface</td>
<td>[27]</td>
</tr>
<tr>
<td>Kosaka H. et al.</td>
<td>9L rat glioma cells and 293 cells</td>
<td>In Vivo, In Vivo</td>
<td>MSC-EGFP or MSC-CD-5-FC resulted in significant prolongation of survival</td>
<td>AdexCAEGFP AdexCADC</td>
<td>[39]</td>
</tr>
<tr>
<td>Schmidt M. et al.</td>
<td>Head and Neck squamous carcinoma cell line FADU</td>
<td>In Vivo</td>
<td>Effective with deletion Mutant of ETA as a Target gene</td>
<td>Gene Switch System</td>
<td>[41]</td>
</tr>
<tr>
<td>Cottin S. et al.</td>
<td>Glioblastoma</td>
<td>In Vivo</td>
<td>Effective against Cx43 cytoplasmic localization</td>
<td>Lentiviral delivery of HSV-lk/GCV</td>
<td>[40]</td>
</tr>
<tr>
<td>Kakinoki K. et al.</td>
<td>HCC</td>
<td>In Vivo, In Vivo</td>
<td>Effective against metastasis and control of microenvironment</td>
<td>CCL2/MCP-1 HSV-lk/GCV</td>
<td>[49]</td>
</tr>
<tr>
<td>Sun X. et al.</td>
<td>R3327-AT rat prostate Carcinoma cells</td>
<td>In Vivo, In Vivo</td>
<td>Effective against hypoxic cells</td>
<td>Bifunctionalcytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT) with 5-FU and radiotherapy</td>
<td>[48]</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Cell Line/Model</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Treatment/Findings</td>
<td>Tumor Model</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------</td>
<td>----------</td>
<td>---------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Amano S. et al.</td>
<td>C6 glioma cells</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Safety evaluation of the Stem cell therapy in brain tissue</td>
<td>Rat MSCtk/GCV</td>
</tr>
<tr>
<td>Zhao Y. et al.</td>
<td>U87 glioma and H4 cells</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Effective as cellular Vehicle for targeted suicide genetherapy</td>
<td>Tumor-tropic neural stem cells, HSV-ik/GCV</td>
</tr>
<tr>
<td>Wang C. et al.</td>
<td>NCI-H460-GFP cells</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Effective brain metastasis treatment</td>
<td>NSC line expressing CD and TK</td>
</tr>
<tr>
<td>Yin X. et al.</td>
<td>Bladder cancer with N-methyl-nitrosourea perfusion</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Effective both in extrinsic and intrinsic apoptosis pathways</td>
<td>BI-HSV-ik/GCV</td>
</tr>
<tr>
<td>Leveille S. et al.</td>
<td>Prostate PC3, Breast MCF7, TSA mammary Adenocarcinoma, B-Lymphoma Karpas-422, Melanoma B16-F10</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Synergistic effect of (VSV)-MΔ51 and 5FC</td>
<td>Combination (VSV)-MΔ51-Expressing(CD::UPRT)-5FC</td>
</tr>
<tr>
<td>Cramer F. et al.</td>
<td>SCLC: GLC16, DMS53 andNCH-H69 and NSCLC cancer lines: H1299 and A549</td>
<td>In Vitro</td>
<td></td>
<td>Improved plasmid nucleardelivery</td>
<td>NFnB-DTS in an YCD-YUPRT (SCD)</td>
</tr>
<tr>
<td>Li J. et al.</td>
<td>SGC7901 human gastric cancer cell line</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Effective Cell apoptosis</td>
<td>YCDglyTK and Htet with CPNPs pDNA3.1-CdTERT- ShRNA / YCDglyTK</td>
</tr>
<tr>
<td>Duan X. et al.</td>
<td>C-26</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>DMP Delivered Survivin-T34A gene DMP/S-T34A which induced apoptosis</td>
<td>DOTAP and MPEG-PCL hybrid micelles (DMP)</td>
</tr>
<tr>
<td>Tang Q et al.</td>
<td>Human hepatic cell line (HepG2)</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Survival time and apoptosis</td>
<td>Intratumorally injected KDR-TK, AFP-TK and microbubble Contrast agent with 5-FC and GCV</td>
</tr>
<tr>
<td>Zarogoulidis P. et al.</td>
<td>Lewis lung cancer, SCLC, NSCLC patients</td>
<td>In Vitro</td>
<td></td>
<td>Survival and malignant pleural effusion control with higher efficiency observed for SCLC.</td>
<td>Ad.CD+5-FC</td>
</tr>
<tr>
<td>Yi B. et al.</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>Review and recruiting at the time of publication</td>
<td>Review</td>
</tr>
<tr>
<td>Qiu Y. et al.</td>
<td>A549, 16HBE, SPC-A-1 AndNCH-H520</td>
<td>In Vitro</td>
<td></td>
<td>Specific CA-positive Target gene expression</td>
<td>CEA promoter and double suicide genes TK and CD. pCEA-TK/CD</td>
</tr>
<tr>
<td>Won Y. et al.</td>
<td>C6, U87, F98 and 9L</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Tumor growth Suppressionand locomotor function maintenance</td>
<td>pPOA/HHSV-ik/GCV</td>
</tr>
<tr>
<td>Lu M. et al.</td>
<td>Prostate</td>
<td>Human</td>
<td></td>
<td>Initiatedand recruiting at the time of publication</td>
<td>Replication-Competent Adenovirus- mediated suicide gene therapy</td>
</tr>
<tr>
<td>Ma S. et al.</td>
<td>MCF-7 and MDA-MB-231 Breast cell lines</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Effective antitumor control</td>
<td>Drosophila melanogaster (Dm-dNK)</td>
</tr>
<tr>
<td>Authors</td>
<td>Cell Line/Lineage</td>
<td>In Vitro</td>
<td>In Vivo</td>
<td>Treatment/Results</td>
<td>Ref.</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------</td>
<td>----------</td>
<td>---------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Preuss E. et al.</td>
<td>G62 human glioblastoma cell Line, A549 human lung Carcinoma, SW620 human Colorectal adenocarcinoma Cell line and IPC298 HumanMelanoma cell line</td>
<td>Continuous complete remission</td>
<td>TK007 novel suicide gene</td>
<td>[95]</td>
<td></td>
</tr>
<tr>
<td>Ahn Y. et al.</td>
<td>CT26 murine colon adenocarcinoma cells and AGS human gastric adenocarcinoma cells</td>
<td>Effective combination Suicide immune therapy</td>
<td>shRNA-lentivirus and Ad5.CMV.HSV.tk</td>
<td>[24]</td>
<td></td>
</tr>
<tr>
<td>Gruber C. et al.</td>
<td>SCC</td>
<td>Efficient transfection of RDEB SCC</td>
<td>SLO=PTM</td>
<td>[96]</td>
<td></td>
</tr>
<tr>
<td>Xiong J. et al.</td>
<td>HeLa human cervical cancer Cells, A549 human lung Adenocarcinoma cells, MHCC97 human hepatoma Carcinoma cells and hEL Normal human embryoniv Lung cells</td>
<td>Combinational cancer Promoter responsive to irradiation</td>
<td>Chimeric hTERT promoters, CArG</td>
<td>[82]</td>
<td></td>
</tr>
<tr>
<td>Luo X. et al.</td>
<td>SGC7901 human gastric Cancer cell lines</td>
<td>Higher efficiency with double suicide gene therapy CD/TK</td>
<td>Double suicide gene therapy Ad-survivin/GFP and Ad-survivin/CD/TK</td>
<td>[59]</td>
<td></td>
</tr>
<tr>
<td>Freytag S. O. et al.</td>
<td>Prostate cancer</td>
<td>Transgene expression up to 3 weeks, PSA decline, Acute urinary and gastrointestinal toxicities</td>
<td>Cytosine deaminasa(CD)/herpes simplexvirus thymidine kinase (HSV-1 TK) and 3D-CRT</td>
<td>[92]</td>
<td></td>
</tr>
<tr>
<td>Pandha H. S. et al.</td>
<td>Breast cancer</td>
<td>Efficient selectivity against erb-2</td>
<td>Therapeutic cassette that contains the Escherichis coli cytosine deaminase gene driven by the tumor-specific erb-2 promoter</td>
<td>[57]</td>
<td></td>
</tr>
<tr>
<td>Li N. et al.</td>
<td>HCC cancer</td>
<td>Recurrence free survival</td>
<td>Adjuvant ADV-TK</td>
<td>[91]</td>
<td></td>
</tr>
<tr>
<td>Voges J. et al.</td>
<td>Glioblastoma</td>
<td>Inhomogeneity of tissue formulation distribution</td>
<td>HSV-1-Tk liposomal vector</td>
<td>[88]</td>
<td></td>
</tr>
<tr>
<td>Nasu Y. et al.</td>
<td>Prostate</td>
<td>No serum cytokine changes after treatment, decreased PSA values, Increased CD8+/HLA-DR+ This study confirmed the safety profile at the surrogate marker of HSV-Tk gene therapy.</td>
<td>Ad.HSV-Tk/GCV</td>
<td>[89]</td>
<td></td>
</tr>
<tr>
<td>Rainov N.G. et al.</td>
<td>Glioblastoma</td>
<td>Surgical resection and Radiotherapy or standard therapy plus adjuvant gene therapy during surgery, Progression-free median survival in the gene group was 180 days compared with 1 83 days of control group</td>
<td>RV-HSV-Tk/GCV</td>
<td>[76]</td>
<td></td>
</tr>
<tr>
<td>Xu F. et al.</td>
<td>Head and Neck</td>
<td>Local response</td>
<td>Intratumoral RV-HSV-Tk/GCV</td>
<td>[90]</td>
<td></td>
</tr>
<tr>
<td>Nemunaitis J. et al.</td>
<td>Refractory cancer patients</td>
<td>Salmonella bacterium can be utilized as a delivery vehicle of the cytosine deaminase gene to malignant tissue with low dose 3 x 10^7 CFU/m^2efficiently.</td>
<td>TAPET-CD</td>
<td>[94]</td>
<td></td>
</tr>
</tbody>
</table>
diffuse within the tumor tissue with passive transportation. Their enhanced accumulation is based on the enhanced permeability and retention effect (EPR) [69]. The nanocomplexes are diffused within the tumor due to the increased permeability of the tumor vessels, however; the low clearance prohibits the formulations from getting out. This methodology is mostly used for siRNA but not for DNA plasmid delivery.

An additional advantage of suicide gene therapy is the ability to display the distribution and transgene expression as the therapeutic gene can be used as a reporter gene. The suicide gene therapy system used for this application is the HSV-tk/GCV. The radiolabelled fluoronucleosides analogues of thymidine such as 1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-iodouracil (FIAU) and radiolabelled 9-[4-fluoro-nucleoside analogues of thymidine such as 1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-iodouracil (FIAU) and radiolabelled 9-[4-fluoro-D-arabinofuranosyl] 5-[iodo-3-(hydroxymethyl)butyl]guanine (FHBG) can be used for HSV-tk substrates [70,71].

From the clinical practice point of view, of the great importance is the feature of the CD system, in which the conversion of the 5-FC to 5-FU can be quantified with the nuclear magnetic resonance spectroscopy (NMRS) [73,74].

**Targeted delivery of suicide inducing genes**

Several receptors on living cells have been used as targets for suicide gene therapy, such as, carcino-embryonic antigen (CEA) [29] and vascular endothelial growth factor receptor (VEGFR) [44,43]. Additional receptors that can targeted are: a) epidermal growth factor receptor (EGFR) [98], b) cluster of differentiation 44s (CD44s) [99], c) cluster of differentiation 133 (CD133 aka AC133) [100], c) folate receptor (FR) [101], d) transferrin receptor (TIR) or cluster differentiation 71 (CD71) [102], e) mucins [103], stage specific embryonic antigen 4 (SSEA-4) [104] and f) tumor resistance antigen 1-60 (TRA-1-60) [105]. Using promoters as a method to target specific over-expressed pathways has been used for; a) EGFR [104], b) carcino-embryonic antigen (CEA) [29], c) prostate specific antigen (PSA) [106], d) cyclooxygenases ( Cox) [107], e) transferrin receptor (TIR) [108], f) Cytokeratin 18 and 19 [109] and g) Telomerase-hTERT [110]. Further investigation towards targeted suicide gene therapy is warranted and several efforts are currently in process [22,111] (Table 2).

**Bystander effect**

In the bystander effect, the therapeutic consequences spread beyond the transfected tumor cells. In addition, distant tumor cells or tumor lesions have been observed to regress, although not directly transduced. There are currently five mechanisms investigated for the regression of untransfected cells due to bystander effects: a) release of soluble formulations, b) passage through gap junctions, c) passive transportation, d) stimulation of local microenvironment and e) endocytosis of apoptotic vesicles.

The CD/5-FU system demonstrates stronger local bystander effect than the HSV-tk/GCV. The 5-FU diffuses efficiently within the tumor cells, and does not require cell to cell contact. The GCV trisphosphate mediated bystander effect uses different mechanisms. An additional, mechanism which the HSV-tk/GCV exploits, is the local inflammation and devascularisation, which probably enhance the vascular permeability and the formulation diffuses more efficiently [52]. The distant tumor resistance effect was initially attributed to the immune system stimulation [53]. However, tumor metastasis regression was also observed in immunodeficient SCID mice, which was associated with the release of soluble factors from the primary site of transfection [54]. Regarding the CD/5-FU system the distant tumor control has been linked to the stimulation of natural killer cells, CD8+ and CD4+. In summary, the CD/5-FU system does not use the cell to cell contact to diffuse efficiently, while the HSV-tk/GCV mainly uses the five previously mentioned mechanisms.

**Gene-Immuno-therapy**

In the study by Bondanza A. et al. [45] the interleukin -7 and -15 (IL-7, -15) were used in a leukemia model with herpes simplex virus thymidine kinase (TK). It was observed that thymidine kinase-positive HA-1 and H-Y- specific cytotoxic T cells differentiated into potent anti-leukemia effectors in vitro and in vivo in mouse model. Increased stimulation and infiltration of tumor with CD8+ was also observed.

In the study by Xu Y et al. [46] Lewis lung cancer cell lines and A549 were obtained and used for evaluation of a suicide gene therapy model as immuno-therapy (in vitro/in vivo). The recombinant adenosine virus expressing horseradish peroxidase (HRP) mediated by human telomerase reverse transcriptase (hTERT) promoter (AdhTERTHRP) and murine interleukin-12 (nIL-12) under the control of Cytomegalovirus (CMV) promoter (AdCMVMIL-12) were developed for this study. The administration of AdhTERTHRP/indole-3-acetic acid (IAA) treatment and AdCMVMIL-12 resulted in enhanced tumor inhibition and survival improvement compared to AdhTERTHRP/IAA administration. Additional, evaluation of safety was performed with the collection of blood samples and measurement of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and...
in the epidermal growth factor receptor (EGFR) over-expressing ovarian cancers, the cd's are engineered under the EGFR promoters. Their delivery is guided by the genetically engineered antibodies targeting them to the cancer cells only. Therefore, for example, for the ovarian cancers expressing deletion mutation of the EGFR gene (EGFRVIII), the vectors are bioengineered to target only the cells displaying on their surfaces EGFRVIII. The genetically engineered antibodies are expressed inside the ovarian, testicular, or brain cancer cells, target, and block antioxidative superoxide dismutase Cu, Zn, Mn superoxide dismutase (SOD Mn), catalase, glutathione reductase, and glutathione peroxidase. This pushes the cancer cells into deepening oxidative stress, with the speed contingent upon the intensity of cancer cells' metabolism, which generates free radicals. Importantly, this strategy of the cancer suicide gene therapy has two critical safe-guards. First, the transgenes are delivered to the targeted cancer cells only. Therefore, it does not inflict any harm onto the healthy cells. In the clinical trials, it should translate into minimizing side effects. Associated risks include immunization due to presence of genetically engineered antibodies after multiple applications, which are inherent with using any antibodies. This potential task is minimalized by genetic engineering of Nano-Antibodies [111]. Second, the promoters are driving expression of the therapeutic transgenes only in the cells expressing cancer or tissue specific genes. Although, some of genes may be over-expressed and result in the receptors over-displayed on cancer cells, they may be also present in smaller quantities on healthy cells. For example epidermal growth factor receptors are over-expressed on some cancer cells. This is the basis for using anti-EGFR antibody-Cetuximab (Erbitux) (e.g., for treatment of KRAS wild type colon cancers), which blocks the receptor and sparks immune response aimed at eliminating cancer cells. However, these EGFRs are also present on healthy cells, thus some of the side effects may occur: fevers, rash, anaphylaxis. Although, they will bind to the healthy cells in approximately two orders of magnitude smaller quantities. Therefore, if the transgenes are guided to EGFR, then they are delivered in the quantities saturating proportional numbers of the receptors onto these healthy cells. Moreover, if internalized, they are expressed in the cells. For these reasons, using very specific targeting guides, as well as the choice of the promoters is of critical importance in this endeavor.

### Inducing Cancer Cell Suicide by Transgenic Expression of caspases and DNases

In clinical practice, chemotherapy and radiotherapy trigger activation of multiple signaling pathways leading to apoptosis and complete destruction of the nuclear and mitochondrial DNA. In fact, HSV/Tk/ganciclovir induces apoptosis through the ligand-independent death receptor aggregation, cytochrome release, and activation of caspases, including caspase-3 and -6 [114-115]. These killing mechanisms can further be enhanced by dual specific suicide genes in hypoxic conditions [116]. Human DNase I family DNases, DNase I, DNase X, DNase gamma, and DNaseI are the main executors of death. However, the cancer cells develop mechanisms creating resistance to therapies and / or can reverse these processes [117]. These include expulsion of therapeutics by the family of the ABC transporters expressed in cancer cells [118-120]. However, these include also activating repair mechanisms in those cells [121-122].

### Inducing Cancer Cell Suicide by Targeted, Transgenic Expression of Antibodies against Anti-Oxidative Enzymes

Within the realm of the suicide gene therapy is also an entirely novel strategy for inducing the cancer cells' deaths through transgenic expression of intracellular antibodies [112-113]. In this strategy, the sequences coding for antibodies are cloned into plasmids or viruses under the targeted-cancer-specific promoters. For example, to be used under the targeted-cancer-specific promoters. For example, to be used
MSCs were transfected with an adenovirus carrying enhanced green [39]. Two strategies were used, where the mesenchymal stem cells gene therapy by inoculation, expressing cytosine deaminase 5-FC gene therapy (Table 1). and probably with the addition of CPNPs a future concept for suicide VEGF-targeted RNAi with suicide genes were an effective combination 24 hours of administration. Finally, the study demonstrated that phosphate nanoparticles. Increased apoptosis was observed within the cell line SGC7901. The formulation was again delivered by calcium gene yCDglyTK. The target cancer cell line was human gastric cancer vascular endothelial growth factor VEGF-shRNA and fusion suicide suicide gene therapy as anti-VEGF with a triple-gene vector expressing as no adverse effects were attributed to the methodology used. Moreover, the vector was equipped with the nuclear localization signals driving it into the cell nuclei, thus assuring high levels of expression. Therefore, not only the suicide gene was delivered exclusively to the ovarian cancer cells, but also the cancer suicide inducing gene was expressed efficiently in those ovarian cancer cells only. This approach assured doubled safeguarding measures, as well as efficient expression of the therapeutic transgenes; thus therapeutic effects.

Inducing Cancer Cell Suicide by Silencing Transcripts and Blocking Gene Products for Vascular Endothelial Growth Factor

In the study by Leng A. et al. [43] the authors investigated the concept of anti-vascular endothelial growth factor suicide gene therapy in a human colon cell line mouse model. They designed a cassette to silence the VEGF-A expression by delivering DNA carrying shVEGF-C/CDTK into the cancer cells by calcium phosphate nanoparticles (CPNPs). This is one of the first studies using nanoparticles as a transport for suicide gene therapy. Additionally, the method was safe as no adverse effects were attributed to the methodology used. In the study by Liu et. al. [44], the authors investigated a model of suicide gene therapy as anti-VEGF with a triple-gene vector expressing vascular endothelial growth factor VEGF-shRNA and fusion suicide gene yCDglyTK. The target cancer cell line was human gastric cancer cell line SGC7901. The formulation was again delivered by calcium phosphate nanoparticles. Increased apoptosis was observed within 24 hours of administration. Finally, the study demonstrated that VEGF-targeted RNAi with suicide genes were an effective combination and probably with the addition of CPNPs a future concept for suicide gene therapy (Table 1).

Suicide Gene Therapy Delivered with the Aid of Stem Cells

Stem cells have been used for suicide gene therapy targeting many pathways [35]. In a recent study they were used as a suicide gene therapy by inoculation, expressing cytosine deaminase 5-FC [39]. Two strategies were used, where the mesenchymal stem cells (MSCs) were transfected with an adenovirus carrying enhanced green fluorescent protein gene (AdexCAEGFP) or the cytosine deaminase gene (AdexCADC). Two different types of MSCs were constructed the MSC-CD and MSC-EGFP. The first were used in combination with intraperitoneal 5-FC and demonstrated prolonged survival, however, it showed poor distribution in comparison to MSC-EGFP. In other studies, the stem cells were used as carrier of the transgenes. Moreover, the safety of MSC/Ck stem cell suicide gene therapy was investigated by Amano S. et al. in a C6 glioma cell mouse model [68]. The study was performed to evaluate the safety of this treatment modality by intracranial and intraperitoneal administration. No histological abnormality was observed at the injection site and normal brain tissue. Tumor-tropic neural stem cells (NSCs F3.CD-TK) were investigated to express dual suicide gene therapy of CD and TK [37]. This methodology was investigated in a lung cancer brain metastasis model. The intravenously administered F3 cells migrated to the lung cancer metastatic lesions and with the co-administration of 5-FC and GCV efficient antitumor effect were observed (Table 1).

However, risks of onco genesis, which are associated with using stem cells have to be addressed, as discussed further.

Interventional Suicide Gene Therapy

The concept of interventional suicide gene therapy has been also investigated in liver cancer model in rabbits [26]. The concepts of double gene therapy were investigated: a) wild type p53 and b) thymidine kinase/cytosine deaminase with GCV and 5FC. In total there were five experimental groups. Among them, 2 groups investigated interventional method for vascular tumor embolization in combination with single gene therapy and in 1 group interventional embolization with double gene therapy was investigated. The control group (0.9% NaCl) and the group receiving only interventional embolization did not present any favorable results. The combination of double gene therapy and interventional embolization presented efficient tumor control and an encouraging concept for the future local treatment (Table 1).

Overexpression or Silencing Specific Genes

In the study by Walther W et al. [81] four different cancer cell lines were included in a mouse model. The cell lines were: a) MCF-7 (breast cancer), b) Panc-1 (pancreatic cancer), c) SKMel-5 (melanoma) and d) HCT116 (hepatocellular cancer). The study design was based on the concept, in which cancer cells expressing claudin -3 and -4 will be more sensitive to the proposed suicide gene therapy of wild type Clostridium perfringens enterotoxin cDNA (CPE) (wtCPE) or translation-optimized CPE cDNA (opt CPE). Indeed the MCF-7 and HCT116 cells lines, which overexpressed claudin -3 and -4, showed increased effects upon the tumors. In the Panc-1 minimal effects were observed and in SKMel-5 the therapy was not efficient.

In the study by Ahn Y et al. [24], the Signal Transducer and Activator of transcription 3 (STAT3) silencing was observed to enhance the suicide gene therapy positive antitumor activity. The STAT3 pathway has been associated with uncontrolled tumor proliferation and immune system suppression. The STAT3 was silenced using a shRNA-lentivirus and additionally Ad5.CMV.HSV.tk was administered to promote suicide gene therapy. The dual treatment modality was used in AGS human gastric adenocarcinoma cells and CT26 murine colon adenocarcinoma cells. It was observed that the immune system was stimulated and the cytotoxic activity of CD3+CD8+T-cells was enhanced (Table 1).

Sensitization to Radiotherapy

The concept of radiotherapy enhancement with suicide gene therapy was investigated by Sun X et al. [48] in a rat prostate model. The study design involved a bifunctional suicide gene therapy with cytotoxic deaminase (CD) and uracil phosphoribosyltransferase
by using bispecific and bivalent antibodies or heterospecific, tetravalent the sites of the therapeutic interventions. These were greatly improved major problem with attaining efficient levels of organ reconstruction sorting and fluorescence activated cell sorting [104,105,138,139]. The stem cell biomarkers with the antibodies for magnetic activated cell the stem cells, which are essential for the attaining the intended goals the peripheral blood mononuclear cells. High viability and purity of these lines, stem cell therapy, applied as the means for regenerating of the organs impaired or damaged by cancer and/or by radical therapies, including targeted suicide gene therapies, which are crafted trauma associated with the surgical acquisition of the patients' own trans-differentiation. They have recently been alleviated by generation of the successes in research on stem cells into regenerative medicine, applied as the means for regenerating of the organs impaired or damaged by cancer and/or by radical therapies of cancer, carries the great potential.

Some of the main problems, preventing rapid streamlining of the patients, incompatibility of the human pluripotency stem cells' Biomarkers with those of other species, controversies surrounding the intended goals of the therapy, have been developed based upon the labeling of the stem cell biomarkers with the antibodies for magnetic activated cell sorting and fluorescence activated cell sorting [104,105,138,139]. The major problem with obtaining efficient levels of organ reconstruction in regenerative medicine is targeting and retention of the stem cells to the sites of the therapeutic interventions. These were greatly improved by using bispecific and bivalent antibodies or heterospecific, tetravalent nano-antibodies [140-142]. Some of the risks for iatrogenic triggering of cancerogenesis in the delivered stem cells were significantly reduced by epiblast induction of pluripotency with non-integrating vectors, purified transcription factors, or miRNA. However, a risk of neoplastic transformation of the pluripotent stem cells is still looming over the clinical trials involving pluripotent stem cells. Various strategies for inactivating or destroying pluripotency inducing vectors, as well as, introducing genes aimed at triggering suicide of remaining undifferentiated, pluripotent, stem cells, being at risk of neoplastic transformation, are currently explored [143-147].

As the populations of human pluripotent stem cells, including human embryonic and induced pluripotent stem cells, are very heterogeneous, the first step, which would be desired prior to administering these cells in cell therapy clinical trials, should be an attempt of identifying and removing of the cells, which could potentially turn into neoplasms [148]. Identification of the stage-specific embryonic antigen (SSEA-5) on the neoplasms' generating stem cells and development of monoclonal antibodies for this antigen facilitated depletion of the incompletely differentiated stem cells' batches; thus to reduce the teratoma-forming potential [104,105,149]. Another biomarker of pluripotent stem cells was identified as claudin-6 [150]. Anti-claudin-6 antibodies, modified with toxins, were applied to eliminate residual, undifferentiated cells. Finally, after inducing the directed differentiation, the cells remaining undifferentiated and proliferating, thus creating a risk of neoplastic transformation, were eliminated with the superparamagnetic nano-antibodies [140].

As a safeguarding strategy, human embryonic stem cells potentially destined for therapeutic administration, were genetically engineered to expressing thymidine kinase. Thus, they became sensitive to ganciclovir at the doses far lower than those toxic to the healthy cells [151,152]. With the mechanisms identical to those in suicide gene therapy of cancer outlined above, the undifferentiated cells were efficiently eliminated. Similarly, the human induced stem cells, as well as the human embryonic stem cells were genetically transduced by inserting truncated herpes simplex virus theta thymidine kinase (deltaTK) gene controlled by EF1α or Nanog promoter [153]. This insertion of deltaTK gene did not affect pluripotency of the cells. Nevertheless, expression of thymidine kinase rendered them sensitive to ganciclovir. This created an opportunity to eliminate residual, undifferentiated stem cells.

Finally, selective elimination of proliferating and undifferentiated stem cells, from among differentiating cells, was attained by inducible expression of transgenes for DNases, similarly to the strategy of suicide gene therapy for cancers of ovaries and testes [109].

Cancer Suicide Gene Therapy Applied to Different Cancers

Lung cancer

In the study by Michaelsen SR et al. [47] small cell lung cancer cell (SCLC) lines were treated by suicide gene therapy with the insulinoma-associated 1 (INSM1) promoter-driven (SG) with or without the combination of chemotherapeutic agents. The chemotherapeutic agents used were: a) Etoposide (VP-16), Cisplatin, (CP), Daunorubicin (DAU), Carmustine (BCNU), 5-Fluorocytosine (5-FC) and 5-Fluoracil (5-FU). Two different systems were used to evaluate the sensitivity of the INSM1 promoter driven suicide gene therapy: 1) yeast cytosine deaminase-uracil phosphoribosyl transferase (YCD-YUPRT) with the pro-drug 5-FC or 2) Escherichia Coli nitroreductase (NTR) with the pro-drug SN27866. The results indicate that this methodology was efficient against chemo-sensitive and chemo-resistant SCLC and
chemotherapy plus the suicide gene therapy enhanced further the cytotoxicity of the treatment.

In an effort to enhance the intracellular trafficking of therapeutic DNA the group of Cramer F et al. [28] exploited the concept of utilizing the endogenous nuclear-shuttling activity by using the nuclear factor kappa B (NFkB). Several SCLC cancer cell lines such as: GLC16, DMS53 and NCI-H69 and non-small cell lung cancer: H1299 and A549 were used in the experiments. The DNA nuclear targeting sequence (DTS) was recognized by the nuclear factor kappa B and the plasmid nuclear delivery was augmented. This study was the first of its kind where intracellular DNA trafficking was increased with this method.

In the study by Mader RM et al. [8] chemo-resistant CCL227 colon cancer cell line (of low and intermediate chemo-resistance) was used in vitro to evaluate whether suicide gene therapy was efficient against chemo-resistant tumors. The conversion of the pro-drug 5-FC was 100% with the tumor associated promoters carcino-embryonic antigen (CEA) and H19 suicide systems. However; it should be noted that this colon cell line had low resistance to chemotherapy agents in comparison to other cancer cell lines such as SCLC (H69-VP, H69-CPR, H69-DAU, H69-BCNU) (Table 1).

Hepatocellular

In the study by Sia KC et al. [9] the HCC 26-1004 hepatocellular cancer cell line was used to evaluate a suicide gene model. The herpes simplex virus type 1 (HSV-1) ampiclon viral vector was coupled with yCD 5-FC administration. The HCC 26-1004 tumor xenografts expressed high levels of yCD genes, as it was displayed with non-invasive imaging. The firefly luciferase reporter gene was not compatible in order to be used in clinical gene therapy trials, however; remained a valuable tool to monitor the activity and bio distribution of the therapeutic gene expression. Additionally, the authors proposed that a future protocol could include radiation as 5-FU is a known radiosensitizer agent [74] (Table 1).

Medulloblastomas

In the study by Li S et al. [30] the neural stem cell line C17.2 was obtained and used with herpes simplex virus thymidine kinase (HSVtk) and ganciclovir (GCV) in a suicide gene therapy model. The non-toxic Ganciclovir was converted to the toxic GCV triphosphate. The phosphorylated GCV molecules were known to move between gap junctions. The abnormal tumor structure was known for the impaired gap junction intercellular communication (GJIC), which played a major role in tumor evolution and drug blocking [75]. In order to enhance the bystander effect the all-trans retinoic acid (ATRA) was used to induce the expression of Cx43 in Daoy cells. The Daoy and C17.2-tk cells were cultured in the presence and absence of ATRA. The colorimetric assay for measuring the activity of cellular enzymes that reduce the tetrazolium dye (MTT) test was used to evaluate the cell viability. The results demonstrated efficient tumor growth control. However; brain tumor control with this method in human trials presented discouraging results [76]. The main reason is the failure of the HSV-tk Vector to efficiently disseminate throughout the tumor cells. This may resulted from the abnormal gap junctions in those tumors. Therefore the ATRA, a lipophilic molecule, was an excellent addition because of its property to cross the blood brain-barrier without any additional toxicity to the body. The ATRA enhanced the GJIC function and tumoricidal effect of the bystander effect (Table 1).

Glioblastomas

A lentiviral delivery of the herpes simplex virus thymidine kinasegene with gancyclovir treatment was found to have efficient bystander effects in glioblastoma cell lines [40]. This was due to the connexin 43 (Cx43), which can be found differently expressed in different glioblastoma cell lines. In the study by Cottin S. et. al. [40] the authors investigated the effect of positive Cx43 and whether the localization of Cx43 plays a role in the treatment efficacy. Although the aberrant localization should have a negative impact for the efficiency of the suicide gene therapy it did not in this case. These findings presented useful data for the design of chemotherapy drugs that rely on the gap junction-mediated bystander effect.

The non-viral vector poly (oligo-D-arginine) was chosen to deliver the HSV-tk/GCV suicide gene therapy in four different glioma cell lines (C6, U87, F98 and 9L). The specific non-viral vector has demonstrated low toxicity and efficient tumor growth suppression. The authors designed an excellent spinal cord cancer model and evaluated the locomotor activity in correlation to tumor control. The locomotor activity was maintained throughout the treatment. This study presented favorable data regarding the non-viral vectors utility in suicide gene therapy. However; there is still a long way until we have a safe non-viral vector [66,65]. The non-viral vectors have also different gene transfection efficiency depending upon the tissue they target (Table 1).

Neuroendocrine tumors

Neuroendocrine tumors are known to have reactivated the insulinoma-associated protein-1 (INSM1). Several neuroendocrine cancer cell lines were used by Akerstrom V et al. [31] with HSV-tk suicide gene therapy to generate the Ad-K5 virus. Improvements of the INSM1 promoter resulted in more selective adenovirus and therefore a more efficient treatment for high risk neuroendocrine tumors (Table 1).

Colon Cancer

In the study by Finzi et al. [25] the concept of enhancing gene transfer based on the synchronization of cell cycle was investigated with three different drugs: a) methotrexate (MTX), b) ara-C and aphidicolin. Two colon cell lines were used in this experiment the HT29 and DDHK12. Three drugs induced different cell cycle synchronization. The retroviral HSV-tk was used for suicide gene therapy. The cell cycle synchronization offered increased number of cells being accessible to drug targeting DNA and therefore improved the action of anti-proliferative chemotherapies. The S phase had been extensively investigated. The use of MTX for cell cycle synchronization was the most effective within 24 hours of suicide gene therapy administration.

In an effort to augment the synergistic effect against human gastric cancer cell lines the group of Li J et al. [77] constructed a novel vector the pcDNA3.1(-)-hTERT-shRNA/sCDglyTK. The interfering RNA (RNAi) targeted the human telomerase reverse transcriptase (hTERT). The plasmids were delivered to the cancer cells with phosphate nanoparticles (CPNPs). The new vector was efficient and using RNAi to target hTERT resulted in a synergistic effect with suicide gene therapy (Table 1).

Head and Neck

The mifepristone-dependent Gene Switch was used to regulate the expression of a deletion mutant Pseudomonas exotoxin A in a squamous head and neck cancer cell line. The Gene Switch system
consists of two plasmids the pSwitch and the pGene/V5-His’s plasmid, from which the toxin mutant pGene/V5-His’s-ETA was, cloned [41]. Currently there is no receptor-mediated cancer therapy for head and neck cancer since there is no surface biomarker exclusively expressed in this type of carcinoma. The study by Schmidt M et al. revealed in vitro that the use of toxin genes in combination with Gene Switch System could be one day a treatment for head and neck cancer (Table 1).

Bladder Cancer

The group of Yin X et al. [36] investigated the bifidobacterium infantis (Bj)-mediated-HSV/GCV suicide gene therapy in a bladder cancer model. N-methyl-nitrosourea perfusion was used to create bladder cancer in mice and three groups were studied. The group A receiving normal saline, group B receiving the complex Bj/PGEX-1AT and the group C receiving BI-TK. The group C presented effective apoptosis in extrinsic and intrinsic pathways with the expression levels of Fas, FasL, Cyt-C and caspase-9 being also significantly higher than group B. The BI can infect the tumor cells effectively, however the underlying mechanisms, in which /tumor cells/ and escape suicide gene therapy, still remain to be elicted (Table 1).

Breast Cancer

Two breast cancer cell lines the MCF7 and MDA-MB-231 were used to evaluate antitumor efficiency of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK) due to the broad substrate specificity. The Dm-dNK was used as a combined suicide gene therapy with chemotherapy. The pro-drug/ Dm-dNK when compared to HSV-1-tk was more efficient due to the broad substrates’ specificity. They were both located in the nucleus when expressed in human cells [78]. A number of mutations observed in Dm-dNK conferred to higher cytosolic localization and catalytic activity [79]. Low toxicity was observed in non-transduced cells and higher tumor inhibition was demonstrated in Dm-dNK/arac positive tumors (Table 1).

Discussion

One of the major challenges in suicide gene therapy is the activation of specific pro-drugs. Therefore, there is currently the urgent need for novel systems activating more pro-drugs. Along these lines, the thymidine-activated mutant of dCK, dCK.DM.574E was created which activates multiple pro-drugs such as; BVdU, LdUNAs and LdT. This system has the ability to sensitize and re-sensitize tumors to chemotherapy agents. Furthermore, it was observed that prevents multidrug resistance to be induced and finally it can simultaneously activate more than one pro-drug without any additional side effects [83].

In an effort to enhance the suicide gene therapy the local administration to the tumor site has been investigated without any remarkable histological adverse effects in lung cancer patients, and in glioma cancer cell lines [6,68]. However, loco-regional administration is not always possible. Therefore the ‘Trojan horse’ approach has been investigated. The concept relies on the ‘stealth’ ability that tumor- tropic neural stem cells (NSCs) have for a sustained release gene expression products. In the study by Zhao Y et al. (2012) the NSCs derived from HES1 human embryonic stem cell line had the ability to migrate from the injection site (vein systemic administration) or intracranial to the intracranial glioma xenografts. A baculovirus vector was used to insert the HSV-tk suicide gene into the cells. Additionally, ganciclovir was administered in order for an amount of concentration to be present locally for the suicide system to act. It was also observed that the transgene expression was present for three weeks. This study presented additional data regarding a sustain release system, which was much needed for suicide gene therapy and a future concept for this treatment modality [38]. The same concept has been also applied with MSC in a HCC model [84]. Additionally, Wang C et al. [37] investigated NSCs (F3) as dual suicide gene therapy with CD and TK creating the NSC-F3.CD-TK and the result was enhanced antitumor activity against lung cancer metastasis in comparison to single suicide gene therapy. The same technique was again used in lung cancer cell lines with a carcinoembryonic antigen (CEA) promoter with TK and CD constructing the pCEA-TK/CD [29]. Dual suicide gene therapy was also investigated with surviving promoter with Ad-surivin/GFP and Ad-surivin/CD/TK and higher efficiency was observed again with the dual in comparison to single suicide gene therapy [62].

Further to the previous concept of combination suicide gene therapy the administration of (VSV)-MA51-expressing (CD::UPRT)-5FC was investigated in four different cancer cell lines (Prostate PC3, Breast MCF7, TSA mammary, Adenocarcinoma, B-Lymphoma Karpas-422, and Melanoma B16-F10) and increased tumor oncology was observed [85]. The combination treatment was more effective against the TSA mammary adenocarcinoma. Although combination treatments might demonstrate efficiency in comparison to single gene therapy approach this was not applicable to all cancers.

A method to enhance the local treatment was investigated by Tang Q et al. [51], for a human hepatic cancer cell line model intratumoral administration of KDR-TK and AFP-TK with microbubble contrast agent prior to ultrasound treatment. The pro-drugs 5-FC and GCV were administered after the intratumoral therapy. The survival time did not differ between treatment groups, however, an increased tumor inhibition rate was observed.

It should be mentioned at this point that the time of the pro-drug administration plays a crucial role in the efficiency of suicide gene therapy, as the pro-drug has to be already diffused within the target tissue for the administered gene therapy to effectively kill the cancer cells. Diffusion of the plasmid is also crucial and several methods of local transport have been presented.

Nanomedicine has been used efficiently in many treatment modalities [4]. In a suicide gene therapy model the group of Duan X et al. [50] explored the gene transfection of the novel cationic self-assembled DOTAP and MPEG-PCL hybrid micelles (DMP). The new transport had less toxicity when compared to the polymer Polyethyleneimine (PEI) with 25kDa. The DMP delivered efficiently the urvivin-T34 gene (S-T34A) to treat C-26 colon cancer cell lines. Efficient metastasis and malignant ascites effusion control was observed. CPNP’s nanoparticles have been also used in previous studies [44,77].

Patient studies with suicide gene therapy are still limited and every effort towards this treatment modality is welcomed [6,63,64,87,76,88-92,60,93,94]. Recently the first clinical trial design for early prostate cancer was published [33,92].

Moreover, novel suicide genes such as the TK.007, have already been introduced and demonstrated efficiency in several cancer cell lines (G62 human glioblastoma cell line, A549 human lung carcinoma, SW620 human colorectal adenocarcinoma cell line and IPC298 human melanoma cell line) [95]. The TK.007 demonstrated higher gene transfection in comparison to HSV-tk with lower doses of GCV and especially to G62 glioblastoma cell line. Another method to enhance the specificity has been achieved with the spliceosome-mediated RNA trans-splicing technology. This technology has the ability to replace
a tumor-specific transcript with one encoding a cell death-inducing peptide/toxin. The group of Gruber C et al. [96] investigated the efficiency of 3’ pre-trans-splicing molecules (PTM) and the results indicated that this method is efficient against highly malignant tumors. Another novel suicide gene therapy system was developed by Di Stasi et al. [97]. The new system targets the inducible caspase 9 (iCasp9) gene. It was applied to children who developed graft-vs-host disease (GVHD) by donor lymphocytes. That process was reversed with the novel suicide gene therapy.

There are currently available several delivery and effector systems at work for suicide gene therapy. Each of them demonstrating effectiveness against specific cancer cell lines. Combining different systems has demonstrated enhanced antitumor efficiency. Combination with interventional techniques has also demonstrated enhanced tumor control in less time than a single modality therapy in tumor models involving extensive tumor vascularization.

Regarding the non-viral vectors there are novel molecules that are being constructed in order to present low toxicity and high DNA loading capacity. Several new pathways as targeted suicide gene therapy are under investigation along with new promoters of over-expressed genes. Suicide gene therapy has presented data where although the drug formulation is injected to a distant site of the primary disease it can efficiently control the primary lesion. The same is observed for distant metastases control. The suicide gene therapy enhances the immune system not only locally, but also distally to the metastatic sites.

Finally, each system uses a different mechanism of diffusion. Nanomedicine has the potential to offer nanoparticles as a transporting mode which is much needed to bypass the increased interstitial fluid pressure of the tumor and to increase the EPR effect. Efficient suicide therapy depends not only on the characteristics of the targeted tissue, but the organ bearing the tumor. The study design should be based on both parameters.

Source of Funding

Marek Malecki, MD, PhD, was Principal Investigator on the projects supported by the funds from the National Institutes of Health [grant numbers: P41 RR000570 and P41 RR002301]; from the National Science Foundation [grant numbers: 9420056, 9522771, 9902020, and 0094016]; and from the Phoenix Biomedical Engineering Foundation [grant number: 2006071401]. Lorny Yarmus, MD was Principal Investigator on the projects supported by the fund from the National Institutes of Health [grant number: R42CA141907-03].

Administrators of the funding institutions and managers of the facilities had no influence on the data presented.

References


